Advanced Medical Solutions Group remains in a Takeover Offer Period as it moves towards a planned Acquisition by H.B. Fuller. The tissue-healing technology Business agreed in June 2026 to a recommended cash deal valuing it at about £659m, and a steady stream of dealing disclosures from investors under the Takeover Code continued into mid-November 2026. The company also issued Rule 2.9 announcements confirming its Share Capital on 9 and 13 November.

What the company does

AMS describes itself as a tissue-healing technology company. It makes surgical products, including tissue adhesives, sutures and biosurgical devices, as well as woundcare dressings. Surgical is now the larger of its two divisions, boosted by the acquisition of Peters Surgical in July 2024. The company has been one of the larger healthcare names on AIM.

Latest developments

The path to a sale began on 20 April 2026, when AMS confirmed it was in discussions with TA Associates about a possible offer for the whole company, starting a formal offer period. TA was given a deadline of 16 May 2026 to make a firm offer or walk away.

On 25 June 2026, however, a recommended cash acquisition was announced with a different buyer: H.B. Fuller Company, acting through its Subsidiary H.B. Fuller Medical Adhesive Technologies. The terms were 285p in cash per AMS share, valuing the group at about £659m. H.B. Fuller said the deal would expand its total addressable market by $15bn to $95bn and estimated annual run-rate Revenue and cost synergies of about $55m by 2031. It said completion was expected by the end of 2026, subject to customary conditions and regulatory approvals.

The material reviewed for this article did not include the outcome of any Shareholder or court process, so the precise stage of completion could not be confirmed.

Financial and Dividend picture

AMS's last full-year figures, published on 18 March 2026 for the year to 31 December 2025, showed revenue up 29% to £228.9m. Surgical revenue rose 35% to £183.5m and woundcare grew around 9% to about £45.4m. Adjusted EBITDA increased 24% to £49.9m, adjusted profit before tax rose 15% to £33.9m and reported profit before tax was £17.8m. Net Debt fell to £50.5m from £55.8m.

The board proposed a total dividend of 2.86p per share for 2025, up 10%, comprising an interim of 0.85p and a final of 2.01p. At the time, it said it was confident of delivering 2026 revenue and EBITDA in line with consensus of £245.3m and £55.2m respectively.

Sector and index context

AMS has been a prominent healthcare constituent of the FTSE AIM All Share Index, and its pending exit would remove one of the market's more substantial medical technology companies. The deal fits a wider pattern of UK-listed small and mid-sized companies attracting bids from Overseas Trade buyers and private equity, a trend that has steadily reduced the number of established growth companies on AIM.

Key risks

The main uncertainty for shareholders is whether the transaction completes on the expected timetable. Regulatory approvals remain a condition, and any delay or objection could postpone or derail the deal. If the acquisition did not proceed, the shares would again reflect the company's standalone prospects, including the integration of Peters Surgical and its debt position. Once completed, AMS would cease to be quoted on AIM.

What to watch next

Investors will watch for confirmation that the remaining conditions, including regulatory clearances, have been satisfied and for an announcement on the timing of completion and the cancellation of the shares from trading on AIM. Any statement on the final timetable is likely to be the next significant update from the company or H.B. Fuller.